34. Neurofibromatosis Clinical trials / Disease details
Clinical trials : 133 / Drugs : 186 - (DrugBank : 67) / Drug target genes : 79 - Drug target pathways : 190
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03513757 (ClinicalTrials.gov) | March 4, 2018 | 4/2/2018 | Dexmedetomidine and Propofol for Pediatric MRI Sedation | An Observer-blinded Randomized Study of Propofol Infusion vs Bolus Dexmedetomidine and Propofol Sedation for Pediatric Magnetic Resonance Imaging | Headache;Tumor;Seizure Disorder;Neurofibromatoses;Hydrocephalus;Abdominal Neoplasm;Spine Deformity | Drug: propofol;Drug: Dexmedetomidine;Drug: Glycopyrrolate;Drug: Lidocaine 1% Injectable Solution;Drug: Nitrous Oxide;Drug: Sevoflurane | Medical College of Wisconsin | NULL | Completed | 12 Months | 60 Months | All | 40 | Phase 4 | United States |